Company Information
CIN
Status
Date of Incorporation
20 October 2004
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
960,437,360
Authorised Capital
970,000,000
Directors
Suryadevara Murali Krishna
Director/Designated Partner
over 2 years ago
over 2 years ago
Saibaba Reddy Eadala
Director/Designated Partner
over 2 years ago
over 2 years ago
Surender Reddy Geedipalli
Director/Designated Partner
over 2 years ago
over 2 years ago
Pulicherla Ganesh
Director/Designated Partner
about 4 years ago
about 4 years ago
Ayodhya Rami Reddy Alla
Beneficial Owner
almost 6 years ago
almost 6 years ago
Ramakrishna Reddy Munnamgi
Director/Designated Partner
about 6 years ago
about 6 years ago
Vullangula Siva Prasad
Director
almost 11 years ago
almost 11 years ago
Past Directors
Bhavanam Mastan Reddy
Director
about 10 years ago
about 10 years ago
Mohan Bandari
Whole Time Director
over 12 years ago
over 12 years ago
Yoganjaneya Reddy Panem
Director
about 14 years ago
about 14 years ago
Goutham Reddy Mereddy
Additional Director
almost 17 years ago
almost 17 years ago
Kanjula Madan Mohana Reddy
Director
over 18 years ago
over 18 years ago
Patents
The present invention relates to an improved process for the preparation of valsartan Formula I and its pharmaceutically acceptable salts.
Fig.
The present invention relates to an improved process for the manufacture of Olmesartan and its pharmaceutically acceptable salts and esters thereof, as active ingredients of a medicament for the treatment of hypertension and related diseases and conditions.
Olmesartan medoxomil, is chemically described as Olmesarta...
The invention relates to a novel process for the preparation of (S,S)-2, 8-Diazabicyclo(4, 3, 0) Nonane of Formula I Which is useful as an intermediate in the preparation of Moxifloxacin.
The present invention is directed to a process for the preparation of enantiomerically enriched β-amino acid derivatives which are important chiral building blocks and intermediates in pharmaceuticals. More specifically, the invention pertains to a novel process for practically convenient and economically producing ...
The invention relates to an improved process for the purification of trityl candesartan of formula I
Formula I which is useful as an Intermediate in the preparation of Candesartan Cilexetil.
The invention relates to a novel process for the preparation of (S)-Methyl-2-amino-2-(2-chlorophenyl) acetate hydrochloride of Formula I which is useful as an Intermediate in the preparation of Clopidogrel bisulphate.
The invention relates to a novel process for the preparation of (R)-5-(2-Aminopropyl)-2-methoxybenzenesulfonamide and its acid addition salts.
Formula I is a useful intermediate in the preparation of Tamsulosin.
The invention relates to an improved process for the preparation of 2-Cyano-4"-formyl biphenyl of Formula I
which is useful as an Intermediate in the preparation of Valsartan.
The present invention relates to a novel process for the preparation of 2-methyl-4H-3-thia-4, 9-diazabenzo[/]azulen-10-ylamine hydrochloride of Formula I,
an useful intermediate in the preparation of Olanzapine.
The invention relates to a novel process for the preparation of (4S)-6-chloro-4-(cyclopropylcthynyl)-1.4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one (Effavirenz) of Formula I, are useful as human immunodeficiency (HIV) reverse transcriptase inhibitors.
The present invention relates to an improved process for the preparation of Blonanserin.
Blonanserin, 2-(4-ethylpiperazin-1 -yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b] pyridine is an atypical antipsychotic. Blonanserin exhibit potent binding property to serotonin (S2) and dopamine (D2) receptors, the...
The invention relates to an improved process for the preparation of N-(1-Oxopentyl)-N-[[2"-(1H-tetrazol-5-yl) 11,1"-biphenyl [-4-yl ]methyl ]-L-valine (i.e Valsartan) which is used as an anti hypertensive drug. The invention has the advantage of reduced number of isolated steps. The process of the present invention ...
Registered Trademarks
[Class : 1] Manufacturing Bulk Drugs (“Bulk Drugs” Means Active Pharmaceutical Ingredient (The Active Chemical Substances In Powder Form, The Main Ingredient In Pharmaceuticals – Chemicals Having Therapeutic Value).
Charges
28 March 2016
Axis Bank Limited
85 Crore
25 November 2008
State Bank Of India
55 Crore
09 September 2008
State Bank Of India
82 Crore
29 November 2006
Bank Of India
15 Crore
20 September 2005
Axis Bank Limited
13 Crore
31 March 2014
Idfc Limited
100 Crore
24 March 2014
Idfc Limited
37 Crore
29 May 2009
Andhra Bank
81 Crore
24 July 2008
Development Credit Bank Limited
10 Crore
29 November 2006
Bank Of India
0
31 March 2014
Idfc Limited
0
24 March 2014
Idfc Limited
0
24 July 2008
Development Credit Bank Limited
0
25 November 2008
State Bank Of India
0
09 September 2008
State Bank Of India
0
20 September 2005
Axis Bank Limited
0
28 March 2016
Axis Bank Limited
0
29 May 2009
Andhra Bank
0
29 November 2006
Bank Of India
0
31 March 2014
Idfc Limited
0
24 March 2014
Idfc Limited
0
24 July 2008
Development Credit Bank Limited
0
25 November 2008
State Bank Of India
0
09 September 2008
State Bank Of India
0
20 September 2005
Axis Bank Limited
0
28 March 2016
Axis Bank Limited
0
29 May 2009
Andhra Bank
0
29 November 2006
Bank Of India
0
31 March 2014
Idfc Limited
0
24 March 2014
Idfc Limited
0
24 July 2008
Development Credit Bank Limited
0
25 November 2008
State Bank Of India
0
09 September 2008
State Bank Of India
0
20 September 2005
Axis Bank Limited
0
28 March 2016
Axis Bank Limited
0
29 May 2009
Andhra Bank
0
Documents
Form PAS-6-06112020_signed
Form CHG-4-31102020_signed
CERTIFICATE OF SATISFACTION OF CHARGE-20201031
Form MSME FORM I-30102020_signed
Letter of the charge holder stating that the amount has been satisfied-30102020
Form PAS-6-11092020_signed
Form DIR-12-07092020_signed
Optional Attachment-(2)-05092020
Optional Attachment-(1)-05092020
Form DPT-3-13082020-signed
Evidence of cessation;-07082020
Form DIR-12-07082020_signed
Optional Attachment-(1)-07082020
Form MSME FORM I-30062020_signed
Form DIR-12-30062020_signed
Optional Attachment-(1)-30062020
Optional Attachment-(2)-30062020
Form MSME FORM I-30042020_signed
Form DIR-12-31012020_signed
Evidence of cessation;-31012020
Optional Attachment-(1)-31012020
Form BEN - 2-28122019_signed
Declaration under section 90-28122019
Form MGT-7-12122019_signed
Optional Attachment-(1)-10122019
Optional Attachment-(2)-10122019
List of share holders, debenture holders;-10122019
Copy of MGT-8-10122019
Form DPT-3-18112019-signed
Form INC-28-07112019-signed
